Erschienen in:
01.11.2006 | Oral Presentation
Benefits of combined treatments using antiresorptive agents and cytotoxic drugs
verfasst von:
I Holen, H Neville-Webbe, RE Coleman
Erschienen in:
Breast Cancer Research
|
Sonderheft 2/2006
Einloggen, um Zugang zu erhalten
Excerpt
Breast cancer patients often receive a combination of different therapies, but our understanding of how best to utilise such combinations to achieve maximal benefit for the patients is incomplete. We have investigated the ability of the antiresorptive agent zoledronic acid (Zol) and the commonly used chemotherapy agents paclitaxel (Pac) and doxorubicin (Dox) to induce apoptotic breast cancer cell death in vitro. …